Skip Page Header

Home > Report to the National Advisory Committee on Drugs on "use of lofexidine in the management of opiate dependence syndrome".

National Medicines Information Centre. (2002) Report to the National Advisory Committee on Drugs on "use of lofexidine in the management of opiate dependence syndrome". Dublin: Stationery Office.

[img]
Preview
PDF (Use of lofexidine in the management of opiate dependence syndrome) - Published Version
980kB
[img]
Preview
PDF (Summary of use of lofexidine ) - Supplemental Material
54kB

Lofexidine is a structural analogue of clonidine and reduces withdrawal symptoms for opiate dependent patients. The activity of lofexidine is not prevented by naloxone. This review evaluates the usefulness of lofexidine as a treatment option in the management of opiate dependency. All the available data in the field was consulted and experts in Ireland were contacted. Clinical trials for lofexidine showed that it appeared to be at least as effective as clonidine and reducing doses of methadone for use in the treatment of opiate withdrawal. The evaluation also showed that lofexidine was as effective as clonidine for managed withdrawal without risks of hypertension. Workers in the field have suggested that lofexidine is more effective in younger patients and those who have a shorter, less entrenched history of opiate use. The review suggests that lofexidine may be useful as an additional treatment for managed opiate withdrawal.


Date
2002
Call No
REF, NACD
Pages
36 p.
Publisher
Stationery Office
Corporate Creators
National Medicines Information Centre
Place of Publication
Dublin
ISBN
0-7557-1784-8
Keywords
AOD withdrawal syndrome, AODD treatment, harm reduction, harm reduction policy, heroin, Ireland, lofexidine, opiate withdrawal agents
Notes
Includes tables, bibliographic references and questionnaire.
EndNote
Accession Number
HRB 2175 (Available), HRB 2176 (Available), HRB 2174 (Available)
Related URLs

Repository Staff Only: item control page